Is McKesson Corporation (MCK) a Buy, Sell, or Hold?
McKesson Corporation
NYSE:MCK
$628.5 USD
$2.12 (0.34%)
- Volume
- 397.62K
- Average Volume
- 1.04M
- Market Capitalization
- $79.78B
- P/E Ratio
- 31.90
- Dividend Yield
- 0.31%
- Price Target
- $574.50
- Year High
- $637.51
- Year Low
- $431.35
- Payout Ratio
- $0.13
- Current Ratio
- $0.91
Industry, Sector & symbol
| Stock Exchange | New York Stock Exchange |
| CEO | Mr. Brian S. Tyler Ph.D. |
| Industry | Medical - Distribution |
| Sector | Healthcare |
| Current Symbol | MCK |
| CUSIP | 58155Q103 |
| CIK | 0000927653 |
| Web | https://www.mckesson.com |
| Phone | 972 446 4800 |
| Currency | USD |
| Employees | 45000 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -1.90 |
| Payout Ratio | 0.13 |
| Current Ratio | 0.91 |
| Quick Ratio | 0.50 |
| Cash Ratio | 0.04 |
Sales & Book Value
| Annual Sales | $308.95B |
| Price / Sales | 0.24 |
| Cash Flow | 36.50 |
| Price / Cash Flow | 16.98 |
| Price / Book | -26.81 |
Price Target and Rating
| Average Stock Price Forecast | $574.50 |
| High Stock Price Forecast | $715.00 |
| Low Stock Price Forecast | $257.00 |
| Forecast Upside/Downside | 9.40% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 13 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $22.39 |
| Trailing P/E Ratio | 31.90 |
| PEG Ratio | -2.33 |
| P/E Growth | -2.33 |
| Net Income | $3B |
| Net Margin | 0.77% |
| Pretax Margin | 1.03% |
| Return on Equity | -115.33% |
| Return on Assets | 3.50% |
Financials Score
| AltmanZ Score | 5.61 |
| Piotroski Score | 6.00 |
| Working Capital | -5.43B |
| Total Assets | 72.43B |
| Ebit | 4.17B |
| Market Cap | 79.78B |
| Total Liabilities | 75.07B |
Poll Results
About McKesson Corporation (NYSE:MCK) Stock
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and re ... tail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It
2024-11-27 10:06:30
Recently, Zacks.com users have been paying close attention to McKesson (MCK). This makes it worthwhile to examine what the stock has in store.
Why McKesson (MCK) is a Top Value Stock for the Long-Term
2024-11-26 10:40:56
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
McKesson Stock Gains 34.1% YTD: What's Driving the Rally?
2024-11-21 14:05:23
MCK continues to gain because of robust segmental performance and raised fiscal 2025 guidance.
MCK Stock Down Despite Latest Partnership to Boost SCD Treatment
2024-11-21 12:33:00
The availability of the FDA-approved drug via McKesson's cell and gene therapies business is expected to give patients improved treatment options for SCD.
All You Need to Know About McKesson (MCK) Rating Upgrade to Buy
2024-11-13 13:00:26
McKesson (MCK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Frequently Asked Questions
-
What is the current McKesson Corporation (MCK) stock price?
-
McKesson Corporation(NYSE:MCK) stock price is $628.5 in the last trading session. During the trading session, MCK stock reached the peak price of $637.51 while $431.35 was the lowest point it dropped to. The percentage change in MCK stock occurred in the recent session was 0.34% while the dollar amount for the price change in MCK stock was $2.12.
-
MCK's industry and sector of operation?
-
The NYSE listed MCK is part of Medical - Distribution industry that operates in the broader Healthcare sector.
-
Who are the executives of MCK?
-
Mr. Napoleon B. Rutledge Jr. | Senior Vice President, Controller & Chief Accounting Officer
Ms. LeAnn B. Smith | Executive Vice President & Chief Human Resources Officer
Ms. Rachel Rodriguez | Vice President of Investor Relations
Mr. Kirk Kaminsky | President of The US Pharmaceutical & Specialty Solutions Business
Mr. Brian S. Tyler Ph.D. | Chief Executive Officer & Director -
How many employees does MCK have?
-
Number of MCK employees currently stands at 45000. MCK operates from 6555 State Highway 161, Irving, TX 75039, US.
-
Link for MCK official website?
-
Official Website of MCK is: https://www.mckesson.com
-
How do I contact MCK?
-
MCK could be contacted at phone #972 446 4800 and can also be accessed through its website. MCK operates from 6555 State Highway 161, Irving, TX 75039, US.
-
How many shares of MCK are traded daily?
-
The average number of MCK shares traded daily for last 3 months was 1.04M.
-
What is the market cap of MCK currently?
-
The market value of MCK currently stands at $79.78B with its latest stock price at $628.5